Iovino, Claudio http://orcid.org/0000-0003-1984-0555
Peiretti, Enrico
Tatti, Filippo
Querques, Giuseppe http://orcid.org/0000-0002-3292-9581
Borrelli, Enrico http://orcid.org/0000-0003-2815-5031
Sacconi, Riccardo http://orcid.org/0000-0003-2891-2012
Chhablani, Jay http://orcid.org/0000-0003-1772-3558
Agrawal, Hitesh
Boon, Camiel J. F.
van Dijk, Elon H. C.
Cennamo, Gilda http://orcid.org/0000-0003-4253-1929
Lupidi, Marco
Muzi, Alessio
Di Iorio, Valentina
Iglicki, Matias
Smadar, Lital
Loewenstein, Anat
Zur, Dinah http://orcid.org/0000-0003-1147-444X
Article History
Received: 7 November 2020
Revised: 11 February 2021
Accepted: 15 March 2021
First Online: 6 April 2021
Compliance with ethical standards
:
: Financial disclosures: GQ: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Amgen (Thousand Oaks,USA), Bayer Shering-Pharma (Berlin, Germany), Heidelberg Engineering Inc (Heidelberg, Germany), KBH (Chengdu; China), LEH Pharma (London, UK), Lumithera (Poulsbo; USA), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Sifi (Catania, Italy), Sooft-Fidea (Abano, Italy), Zeiss (Dublin, USA). EB: Zeiss (Dublin, USA), CenterVue (Padova, Italy). RS: Zeiss (Dublin, USA). AL: Allergan Inc (Irvine, California, USA), Bayer (Berlin, Germany), Beyeonics (Haifa, Israel), Forsightlabs (CA, USA), Notal Vision (Tel Aviv, Israel), Novartis (Basel, Switzerland), Roche (Basel, Switzerland). DZ: Allergan Inc (Irvine, California, USA), Bayer (Berlin, Germany). The remaining authors declare no competing interests.